A Novel CDC42 Variant with Impaired Thymopoiesis, IL-7R Signaling, PAK1 Binding, and TCR Repertoire Diversity
-
Published:2023-08-15
Issue:8
Volume:43
Page:1927-1940
-
ISSN:0271-9142
-
Container-title:Journal of Clinical Immunology
-
language:en
-
Short-container-title:J Clin Immunol
Author:
Assing Kristian, Jørgensen Sofie E., Sandgaard Katrine S., De Keukeleere Kerstin, B.-Hansen Marie, Petersen Mikkel S., Hartling Ulla B., Vaal Thanis M. K.-de, Nielsen Christian, Jakobsen Marianne A., Watt Eleanor, Adams Stuart, Hao Qin, Fagerberg Christina, Mogensen Trine H.ORCID
Abstract
AbstractGenetic variants in cell division cycle 42 (CDC42) can manifest with dysmorphic features, autoinflammation, hemophagocytic lymphohistiocytosis, and thrombocytopenia, whereas defective thymopoiesis is a rare disease manifestation. We report a novel CDC42 missense variant (c.46A > G, p.Lys16Glu) resulting in infection and HPV-driven carcinogenesis in the mosaic mother and impaired thymopoiesis and profound T cell lymphopenia in the heterozygous daughter identified through newborn screening for SCID. We found that surface expression of IL-7Rα (CD127) was decreased, consistent with reduced IL-7-induced STAT5 phosphorylation and accelerated apoptotic T cell death. Consistent with the vital role of IL-7 in regulating thymopoiesis, both patients displayed reduced T cell receptor CDR3 repertoires. Moreover, the CDC42 variant prevented binding to the downstream effector, p21-activated kinase (PAK)1, suggesting this impaired interaction to underlie reduced IL-7Rα expression and signaling. Here, we provide the first report of severely compromised thymopoiesis and perturbed IL-7Rα signaling caused by a novel CDC42 variant and presenting with diverging clinical and immunological phenotypes in patients.
Funder
Danmarks Frie Forskningsfond Lundbeckfonden Novo Nordisk Fonden Innovationsfonden Royal Danish Library, Aarhus University Library
Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy
Reference35 articles.
1. Baekvad-Hansen M, Adamsen D, Bybjerg-Grauholm J, Hougaard DM. Implementation of SCID screening in Denmark. Int J Neonatal Screen. 2021;7(3):54. 2. Cai Q, Cai J, Fang Y, Young KH. Epstein-Barr virus-positive natural killer/T-cell lymphoma. Front Oncol. 2019;9:386. 3. Coppola S, Insalaco A, Zara E, Di Rocco M, Marafon DP, Spadaro F, Pannone L, Farina L, Pasquini L, Martinelli S, De Benedetti F, Tartaglia M. Mutations at the C-terminus of CDC42 cause distinct hematopoietic and autoinflammatory disorders. J Allergy Clin Immunol. 2022;150:223–8. 4. Cui JH, Lin KR, Yuan SH, Jin YB, Chen XP, Su XK, Jiang J, Pan YM, Mao SL, Mao XF, Luo W. TCR repertoire as a novel indicator for immune monitoring and prognosis assessment of patients with cervical cancer. Front Immunol. 2018;9:2729. 5. Dash P, Fiore-Gartland AJ, Hertz T, Wang GC, Sharma S, Souquette A, Crawford JC, Clemens EB, Nguyen THO, Kedzierska K, La Gruta NL, Bradley P, Thomas PG. Quantifiable predictive features define epitope-specific T cell receptor repertoires. Nature. 2017;547:89–93.
|
|